Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

2.
3.
4.

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.

Suk Danik J, Rifai N, Buring JE, Ridker PM.

J Am Coll Cardiol. 2008 Jul 8;52(2):124-31. doi: 10.1016/j.jacc.2008.04.009.

5.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

JAMA. 1998 May 27;279(20):1615-22.

PMID:
9613910
6.

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.

Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM.

JAMA. 2007 Jul 18;298(3):309-16.

PMID:
17635891
7.

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG.

JAMA. 2009 Jun 10;301(22):2331-9. doi: 10.1001/jama.2009.801.

PMID:
19509380
8.

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR.

N Engl J Med. 2002 Nov 14;347(20):1557-65.

9.

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ.

JAMA. 2012 Mar 28;307(12):1302-9. doi: 10.1001/jama.2012.366. Erratum in: JAMA. 2012 May 9;307(18):1915. JAMA. 2012 Apr 25;307(16):1694.

PMID:
22453571
10.

Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.

Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C; German Diabetes and Dialysis Study Investigators.

Am J Kidney Dis. 2009 Nov;54(5):902-11. doi: 10.1053/j.ajkd.2009.06.029. Epub 2009 Sep 25.

PMID:
19781835
11.

Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.

Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Watanabe K, Watanabe Y, Mishina H, Kugiyama K.

Atherosclerosis. 2011 Sep;218(1):163-7. doi: 10.1016/j.atherosclerosis.2011.04.040. Epub 2011 May 6.

PMID:
21605862
12.
13.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM.

J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9. doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21.

14.

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P.

JAMA. 2005 Apr 6;293(13):1609-16.

PMID:
15811980
15.

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.

Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R; Pro(a)LiFe-Study Group.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2019-27. doi: 10.1161/ATVBAHA.116.307983. Epub 2016 Jul 14.

16.

Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study.

Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, Castelli WP, Schaefer EJ.

Circulation. 1993 Apr;87(4):1135-41.

PMID:
8462142
17.

Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).

Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ.

JAMA. 1995 Dec 13;274(22):1771-4.

PMID:
7500507
18.

Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.

Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM.

Clin Chem. 2004 Aug;50(8):1364-71. Epub 2004 May 20.

19.

Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Liao KP, Liu J, Lu B, Solomon DH, Kim SC.

Arthritis Rheumatol. 2015 May;67(8):2004-10. doi: 10.1002/art.39165.

20.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

Supplemental Content

Support Center